Open AccessCarbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells
Author(s) -
Guanzhang Li,
Ting-Wei Chen,
Ann-Christin Nickel,
Sajjad Muhammad,
HansJakob Steiger,
Theophilos Tzaridis,
Daniel Hänggi,
Reinhard Zeidler,
Wei Zhang,
Ulf D. Kahlert
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s300623
Subject(s) - glioma , brain tumor , carbonic anhydrase , cancer research , cancer stem cell , stem cell , mesenchymal stem cell , biology , medicine , enzyme , pathology , genetics , biochemistry
The metabolic enzyme carbonic anhydrase 12 (CA12/CAXII) emerges as a promising cancer therapeutic target with drug development projects underway. Previous reports proposed the relevance of CA12 in the context of glioma but are limited in patient data quantity, ignore ethnic diversity of patients or rely on semi-quantitative, thereby out of date, methodology. Moreover, little is known on the association of CA12 to brain tumor stemness or on the effect of anti-CAXII-directed monotherapies on glioma stem cells (GSCs), in particular their response regarding mesenchymal differentiation status.